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Background: Incomplete abortions can be managed expectantly, surgically and medically (using misoprostol).  Expectant 
management is safe in places where women have access to information, appropriate care and follow-up; however, in isolated 
and poor areas women who come for help need an intervention.
Objective: To compare the efficiency of manual vacuum aspiration (MVA) and misoprostol in the treatment of incomplete 
abortion.
Patients and method: This was a prospective study over five months from March to August 2015.  All patients admitted with 
a diagnosis of incomplete abortion were recruited into the study. 
Results: 308 patients with incomplete abortion were randomized into two treatment groups - MVA (done under local 
anaesthesia) and misoprostol (400 micrograms by the vaginal route). MVA was successfully performed for all patients. 
Two patients presented with anaemia. In the misoprostol group, 23 patients had vaginal bleeding, and 10 persistence of 
incomplete abortion. 
Conclusion: MVA is more effective than misoprostol with less complications in the treatment of incomplete abortion when 
it is done by a trained person.
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Introduction
Incomplete abortion contributes disproportionately to 
maternal morbidity and mortality in developing countries 
[1]. According to the World Health Organization 87,000 
maternal deaths due to incomplete abortion are recorded 
yearly in developing countries [2]. Incomplete abortions 
can be managed expectantly, surgically and medically 
(using misoprostol with or without mifeprostone). 
Surgical management has been the standard of care 
worldwide for many years, and its safety and effectiveness 
is well proven where there is high-quality medical care [3]. 
In Chad, surgical treatment of incomplete abortion, either 
spontaneous or induced, involves evacuation of the uterus 
with MVA or sharp curettage.  MVA was a recent (2010) 
addition to the management of incomplete abortion in 
our units and other hospitals in N’Djamana [4]. Medical 
management of incomplete abortion using misoprostol is 
gaining ground as a feasible, and low cost means of uterine 
evacuation [1].
Our study aimed to compare the efficiency of MVA 
and misoprostol in the treatment of incomplete abortion 
at N’djamena Mother and Child hospital.
Methods and Patients
This was a prospective study over five months from March 
to August 2015. All patients admitted for incomplete 
abortion were recruited. Each patient was given a detailed 
explanation of both options of management and written 
consent obtained for the study.  Patients that declined 
to take part and those with a diagnosis in addition to 
incomplete miscarriage were excluded from the study.  The 
patients were randomised into the two groups depending 
on the content of the envelope the patient picked from 
a box containing an equal number of envelopes for each 
group.
The procedure of manual vacuum aspiration was done 
under local anaesthesia. Those in the misoprostol group 
received 400 micrograms of misoprostol by the vaginal 
route.
Data were collected and analysed using EPI INFO 
3.5.1 software.
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Period MVA group Misoprostol Group
n (%) n (%)
≤ 12 weeks   34 (22.1)   40 (26.0)
> 12 weeks 120 (77.9) 114 (74.0)
Total 154 (100) 154 (100)
Results
We registered 308 patients with incomplete abortion. 
The majority (n=292/308 i.e 94.8%) presented with 
spontaneous abortion. The remaining 16 were induced 
abortions (5.2%). In the two groups the majority of 
abortions occurred after 12 weeks of pregnancy.
MVA was successfully performed for all patients. Two 
patients presented with anaemia linked with MVA which 
required hospitalization. No uterine perforation was 
noted in the group of MVA.
In the misoprostol group, 23 patients had significant 
vaginal bleeding (14.9%), 10 patients (6.5%) had retained 
placental tissue that required further intervention. 
All patients who received misoprostol complained of 
abdominal pain. A few patients in the misoprostol group 
reported having fever n= 12(7.8%) or vomiting n= 5 
(3.2%).
Patients were treated with amoxicillin and 
metronidazole to prevent infection.
In the MVA group, the majority of patients stayed 
in hospital for less than 12 hours. In the misoprostol 
group, the hospitalization period was 13 – 24 hours for 
two thirds of patients and more than 24 hours for the 
remaining third.  
Discussion
Management of incomplete abortion, whether spontaneous 
or induced, involves evacuation of the uterus with MVA 
or misoprostol with or without the use of mifeprostone 
[5,6]. Most unsafe abortions occur in low-income 
countries where induced abortion is restricted [7] and 
contributes substantially to the global burden of maternal 
mortality and morbidity [8]. Our findings contrast with 
a high proportion of our patients (94.8%) reporting 
spontaneous abortion. African authors such as Cissé [9], 
Lokossou [10] and Baeta [11] have reported a high rate 
of spontaneous abortion as opposed to induced (ranging 
from 70.2%- 83%). Our findings could be explained by 
the fact that some patients did not say they had had an 
induced abortion. Induced abortion is forbidden in Chad, 
so women often claim to have had a spontaneous abortion 
even if it was induced.
Our results confirm previous studies where MVA was 
found to be an effective and useful tool in low resource 
settings for women with incomplete abortion and a 
uterine size of less than 12 weeks [6,7,12].  If uterine size 
at the time of treatment is equivalent to a pregnancy of 
gestational age 13 weeks or less, either vacuum aspiration 
or treatment with misoprostol is recommended for women 
with incomplete abortion. The recommended regimen of 
misoprostol is a single dose given either sublingually (400 
μg) or orally (600 μg) [13].
The misoprostol group reported complications which 
were not reported in the MVA group. Tang [14], reported 
abdominal cramping usually starting within the first 
few hours but it may begin as early as 10 minutes after 
misoprostol administration. The pain may be stronger 
than that experienced during a regular period.
Specific complications linked with misoprostol like 
fever and vomiting were noted in our study. Blum [2] 
reported that chills are a common side effect of misoprostol 
but are transient. Fever is less common and does not 
necessarily indicate infection. An antipyretic can be used 
for relief of fever [14]. Nausea and vomiting may occur 
and will resolve 2 to 6 hours after taking misoprostol. An 
anti-emetic can be used if needed [14].
The hospitalization period was shorter in the MVA 
group than the misoprostol group which agrees with 
earlier studies [2, 9, 14, 15]. 
Conclusion
This study shows that MVA is more efficient than 
misoprostol in the treatment of incomplete abortion. 
More complications are registered for the management 
with misoprostol. We conclude that in remote areas, 
misoprostol can be used when MVA is not possible. 
There should be special training before this so that health 
workers in areas where MVA is not available can inform 
women about cramping and fever and know how to get 
help when they assess the bleeding as ‘too much’ or there 
are retained products.  
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Table 1. Period during pregnancy when abortion occurred 
Period MVA group Misoprostol Group
n (%) n (%)
≤12 139 (90.3)   00 (0)
24 – 13   13 (8.4) 105 (68.2)
>24     2 (1.3)   49 (31.8)
Total 154 (100) 154 (100)
Table 2. Duration of hospitalization
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